Your browser is no longer supported. Please, upgrade your browser.
DRNA [NASD]
Dicerna Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.63 Insider Own0.20% Shs Outstand77.75M Perf Week0.42%
Market Cap2.97B Forward P/E- EPS next Y-2.09 Insider Trans-57.41% Shs Float72.31M Perf Month77.53%
Income-124.40M PEG- EPS next Q-0.69 Inst Own83.30% Short Float3.99% Perf Quarter81.51%
Sales192.90M P/S15.42 EPS this Y13.70% Inst Trans4.13% Short Ratio1.54 Perf Half Y24.00%
Book/sh1.38 P/B27.59 EPS next Y17.60% ROA-16.60% Target Price34.96 Perf Year55.18%
Cash/sh7.24 P/C5.26 EPS next 5Y- ROE-103.10% 52W Range19.06 - 40.14 Perf YTD72.86%
Dividend- P/FCF345.86 EPS past 5Y13.20% ROI-82.20% 52W High-5.13% Beta0.99
Dividend %- Quick Ratio2.50 Sales past 5Y289.20% Gross Margin- 52W Low99.79% ATR1.34
Employees302 Current Ratio2.50 Sales Q/Q28.80% Oper. Margin-62.90% RSI (14)88.62 Volatility0.25% 3.10%
OptionableYes Debt/Eq0.00 EPS Q/Q25.10% Profit Margin-64.50% Rel Volume5.56 Prev Close37.99
ShortableYes LT Debt/Eq0.00 EarningsNov 09 BMO Payout- Avg Volume1.87M Price38.08
Recom2.20 SMA2043.47% SMA5065.33% SMA20037.90% Volume10,408,626 Change0.24%
Aug-11-21Downgrade Goldman Buy → Neutral $36 → $25
Aug-09-21Downgrade Citigroup Buy → Neutral $32
Aug-06-21Downgrade Truist Buy → Hold $32
Aug-06-21Downgrade Cowen Outperform → Market Perform
Apr-16-21Initiated Goldman Buy $48
Mar-02-21Reiterated H.C. Wainwright Buy $35 → $40
Aug-07-20Reiterated H.C. Wainwright Buy $32 → $35
May-13-20Initiated RBC Capital Mkts Outperform $35
Mar-19-20Initiated Berenberg Buy $35
Nov-19-19Reiterated H.C. Wainwright Buy $22 → $30
Oct-29-19Initiated Robert W. Baird Outperform
May-24-19Resumed Citigroup Buy $30
Jan-22-19Upgrade Chardan Capital Markets Neutral → Buy $18
Nov-06-18Upgrade B. Riley FBR Neutral → Buy $13.50 → $21
Sep-13-18Initiated Citigroup Buy $27
Aug-15-18Upgrade H.C. Wainwright Neutral → Buy $21
Aug-09-18Reiterated Stifel Buy $18 → $20
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $10
Mar-23-18Downgrade H.C. Wainwright Buy → Neutral $12
Mar-09-18Initiated Chardan Capital Markets Neutral
Nov-26-21 09:00AM  
Nov-24-21 02:49PM  
Nov-23-21 06:23AM  
01:00AM  
Nov-22-21 06:45PM  
05:00PM  
04:38PM  
03:15PM  
10:25AM  
Nov-20-21 03:05AM  
Nov-19-21 11:15PM  
08:02PM  
10:03AM  
Nov-18-21 08:58PM  
04:21PM  
02:55PM  
02:45PM  
02:31PM  
02:16PM  
01:39PM  
01:34PM  
12:43PM  
11:38AM  
10:58AM  
10:37AM  
09:28AM  
07:20AM  
07:19AM  
07:19AM  
07:00AM  
05:10AM  
04:02AM  
Nov-17-21 03:01AM  
Nov-12-21 08:10AM  
08:00AM  
Nov-09-21 07:00PM  
11:17AM  
08:55AM  
07:30AM  
Nov-04-21 01:15PM  
Nov-02-21 04:05PM  
Oct-28-21 03:06PM  
Oct-19-21 10:39AM  
07:30AM  
Oct-18-21 01:35PM  
Oct-15-21 04:01PM  
Oct-14-21 04:54PM  
Oct-12-21 07:06AM  
Oct-01-21 04:38PM  
Sep-28-21 07:30AM  
Sep-22-21 07:30AM  
Sep-02-21 04:05PM  
Aug-10-21 08:28PM  
Aug-09-21 05:30PM  
08:15AM  
07:00AM  
Aug-08-21 10:03AM  
Aug-06-21 02:43PM  
09:23AM  
Aug-05-21 04:01PM  
Aug-03-21 03:00AM  
Aug-02-21 04:05PM  
Jul-29-21 03:04PM  
07:30AM  
Jul-21-21 08:00AM  
Jul-20-21 09:10AM  
Jul-12-21 03:31PM  
Jul-01-21 04:30PM  
Jun-22-21 07:30AM  
Jun-16-21 07:30AM  
Jun-07-21 06:25AM  
Jun-03-21 04:05PM  
May-28-21 01:33AM  
May-27-21 07:30AM  
May-24-21 12:29PM  
07:30AM  
May-12-21 04:05PM  
May-11-21 10:35AM  
May-10-21 03:28AM  
May-07-21 04:00PM  
May-06-21 06:35PM  
04:05PM  
02:45PM  
Apr-29-21 04:05PM  
Apr-19-21 03:45PM  
Apr-08-21 09:04AM  
07:40AM  
07:30AM  
Apr-01-21 04:45PM  
Mar-30-21 01:59PM  
10:50AM  
Mar-24-21 07:30AM  
Mar-11-21 07:30AM  
Mar-07-21 02:36AM  
Mar-04-21 07:30AM  
Feb-28-21 01:12PM  
Feb-26-21 12:02PM  
Feb-25-21 05:09PM  
04:05PM  
02:30PM  
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brown Bob DChief Scientific Ofr., EVP R&DNov 18Option Exercise3.4224,93685,28125,203Nov 22 04:38 PM
Brown Bob DChief Scientific Ofr., EVP R&DNov 18Sale37.9424,936946,072267Nov 22 04:38 PM
Aradhye ShreeramEVP & Chief Medical OfficerSep 17Sale21.472,05644,1424,969Sep 17 06:48 PM
Zeng LingChief Legal Officer & Sec'ySep 17Sale21.471,33428,6413,222Sep 17 06:48 PM
Brown Bob DChief Scientific Ofr., EVP R&DSep 17Sale21.0621,250447,516267Sep 21 05:37 PM
FAMBROUGH DOUGLASPresident and CEOAug 10Buy22.105,000110,48043,164Aug 10 08:06 PM
KOZIN MARC DDirectorAug 10Buy23.663,00070,9866,333Aug 10 06:44 PM
Brown Bob DChief Scientific Ofr., EVP R&DAug 02Option Exercise3.428,31228,42729,829Aug 03 04:25 PM
Brown Bob DChief Scientific Ofr., EVP R&DAug 02Sale37.388,312310,67821,517Aug 03 04:25 PM
Weissman James BChief Operating Officer & EVPJul 06Option Exercise9.0930,000272,70046,000Jul 08 08:17 PM
Weissman James BChief Operating Officer & EVPJul 06Sale39.0930,0001,172,70016,000Jul 08 08:17 PM
Brown Bob DChief Scientific Ofr., EVP R&DJul 01Option Exercise3.428,31228,42729,829Jul 06 04:18 PM
Brown Bob DChief Scientific Ofr., EVP R&DJul 01Sale37.378,312310,64121,517Jul 06 04:18 PM
Paglia Regina M.Chief Human Resources OfficerJun 25Option Exercise22.581,00022,5801,269Jun 29 04:17 PM
Paglia Regina M.Chief Human Resources OfficerJun 25Sale38.001,00038,004269Jun 29 04:17 PM
Paglia Regina M.Chief Human Resources OfficerJun 22Option Exercise15.5718,435287,11218,704Jun 24 09:25 PM
Paglia Regina M.Chief Human Resources OfficerJun 22Sale36.9918,435681,981269Jun 24 09:25 PM
Paglia Regina M.Chief Human Resources OfficerJun 17Option Exercise18.068,664156,5068,933Jun 22 04:14 PM
Paglia Regina M.Chief Human Resources OfficerJun 17Sale35.798,664310,068269Jun 22 04:14 PM
Paglia Regina M.Chief Human Resources OfficerJun 16Option Exercise16.6731,564526,03431,833Jun 17 09:18 PM
Paglia Regina M.Chief Human Resources OfficerJun 16Sale35.6331,5641,124,627269Jun 17 09:18 PM
Ciappenelli Robert D.Chief Commercial OfficerJun 14Option Exercise15.6120,000312,20023,773Jun 15 07:19 PM
Ciappenelli Robert D.Chief Commercial OfficerJun 14Sale38.0020,000760,0003,773Jun 15 07:19 PM
Brown Bob DChief Scientific Ofr., EVP R&DJun 11Option Exercise9.0910,00090,90031,517Jun 15 07:19 PM
Ciappenelli Robert D.Chief Commercial OfficerJun 11Option Exercise15.6110,000156,10013,773Jun 15 07:19 PM
Ciappenelli Robert D.Chief Commercial OfficerJun 11Sale35.0010,000350,0003,773Jun 15 07:19 PM
Brown Bob DChief Scientific Ofr., EVP R&DJun 11Sale34.0010,000340,00021,517Jun 15 07:19 PM
Brown Bob DChief Scientific Ofr., EVP R&DJun 07Option Exercise9.0910,00090,90031,517Jun 08 07:05 PM
Brown Bob DChief Scientific Ofr., EVP R&DJun 07Sale33.0010,000330,00021,517Jun 08 07:05 PM
Koppel AdamDirectorJun 03Option Exercise0.003,33303,333Jun 07 06:50 PM
Brown Bob DChief Scientific Ofr., EVP R&DJun 01Option Exercise3.428,31228,42729,829Jun 03 09:28 PM
Paglia Regina M.Chief Human Resources OfficerJun 01Option Exercise12.934,43157,2934,431Jun 03 09:35 PM
Paglia Regina M.Chief Human Resources OfficerJun 01Sale30.944,431137,0780Jun 03 09:35 PM
Brown Bob DChief Scientific Ofr., EVP R&DJun 01Sale30.938,312257,07821,517Jun 03 09:28 PM
Paglia Regina M.Chief Human Resources OfficerMay 03Option Exercise12.934,43157,2934,431May 05 04:19 PM
Brown Bob DChief Scientific Ofr., EVP R&DMay 03Option Exercise3.428,31228,42729,829May 05 04:17 PM
Brown Bob DChief Scientific Ofr., EVP R&DMay 03Sale30.288,312251,67221,517May 05 04:17 PM
Paglia Regina M.Chief Human Resources OfficerMay 03Sale30.284,431134,1920May 05 04:19 PM
Brown Bob DChief Scientific Ofr., EVP R&DApr 30Option Exercise9.0910,00090,90031,517May 03 05:40 PM
Brown Bob DChief Scientific Ofr., EVP R&DApr 30Sale32.0010,000320,00021,517May 03 05:40 PM
Brown Bob DChief Scientific Ofr., EVP R&DApr 29Option Exercise9.0910,00090,90031,517May 03 05:40 PM
Brown Bob DChief Scientific Ofr., EVP R&DApr 29Sale31.0010,000310,00021,517May 03 05:40 PM
Weissman James BChief Operating Officer & EVPApr 16Sale29.994,904147,07116,000Apr 20 07:17 PM
Paglia Regina M.Chief Human Resources OfficerApr 01Option Exercise12.934,43157,2934,431Apr 05 09:00 PM
Brown Bob DChief Scientific Ofr., EVP R&DApr 01Option Exercise3.428,31228,42729,829Apr 05 09:42 PM
Brown Bob DChief Scientific Ofr., EVP R&DApr 01Sale25.878,312215,02521,517Apr 05 09:42 PM
Paglia Regina M.Chief Human Resources OfficerApr 01Sale25.864,431114,5640Apr 05 09:00 PM
Paglia Regina M.Chief Human Resources OfficerMar 01Option Exercise12.934,43157,2934,431Mar 02 07:00 PM
Brown Bob DChief Scientific Ofr., EVP R&DMar 01Option Exercise9.098,31275,55629,829Mar 02 07:00 PM
Brown Bob DChief Scientific Ofr., EVP R&DMar 01Sale28.968,312240,70121,517Mar 02 07:00 PM
Paglia Regina M.Chief Human Resources OfficerMar 01Sale28.964,431128,3390Mar 02 07:00 PM
Weissman James BChief Operating Officer & EVPFeb 05Sale26.997,156193,14020,904Feb 08 07:58 PM
Brown Bob DChief Scientific Ofr., EVP R&DFeb 03Option Exercise9.098,31275,55629,829Feb 04 05:11 PM
Brown Bob DChief Scientific Ofr., EVP R&DFeb 03Sale25.008,312207,80021,517Feb 04 05:11 PM
Paglia Regina M.Chief Human Resources OfficerFeb 02Option Exercise12.934,43157,2934,431Feb 04 05:11 PM
Paglia Regina M.Chief Human Resources OfficerFeb 02Sale24.004,431106,3440Feb 04 05:11 PM
Paglia Regina M.Chief Human Resources OfficerJan 25Option Exercise12.934,43157,2936,326Jan 27 06:40 PM
Brown Bob DChief Scientific Ofr., EVP R&DJan 25Option Exercise9.0916,630151,16743,147Jan 27 06:41 PM
Brown Bob DChief Scientific Ofr., EVP R&DJan 25Sale25.0021,630540,75021,517Jan 27 06:41 PM
Paglia Regina M.Chief Human Resources OfficerJan 25Sale25.006,326158,1500Jan 27 06:40 PM
Weissman James BChief Operating Officer & EVPJan 12Sale24.085,808139,86828,060Jan 13 08:20 PM
Brown Bob DSee RemarksJan 12Sale24.075,808139,81726,517Jan 13 08:20 PM
Weissman James BChief Operating Officer & EVPJan 11Sale23.993,80091,16233,868Jan 12 09:40 PM
Koppel AdamDirectorDec 10Sale23.401,000,00023,400,0003,080,237Dec 14 05:35 PM
Weissman James BChief Operating Officer & EVPDec 01Option Exercise3.424,36014,91136,220Dec 03 08:24 PM
Brown Bob DSee RemarksDec 01Option Exercise3.428,18527,99334,702Dec 03 08:26 PM
Weissman James BChief Operating Officer & EVPDec 01Sale25.214,360109,90331,860Dec 03 08:24 PM
Brown Bob DSee RemarksDec 01Sale25.198,185206,20626,517Dec 03 08:26 PM